L-208-2021

Agreement ID
L-208-2021
Lead IC
NCI
Exclusivity
Exclusive
External Party
Athenex, Inc.
Fiscal Year
2022
Territory
Worldwide
Execution Date
Effective Date
Export Date
Technologies
TAB-4297     T Cell Receptors Targeting p53 Mutations for Cancer Immunotherapy and Adoptive Cell Therapy
TAB-4370     T cell Receptors Which Recognize Mutated EGFR